Thanks, Ryan. Yesterday afternoon, we reported our strongest quarter since the fourth quarter of 2017. As shown on slide five of the presentation we posted yesterday, we increased revenue, net income, and adjusted EBITDA in every quarter during 2024. Last year was a remarkable year in terms of consistent growth and execution, culminating with an outstanding fourth quarter which included the following highlights. It was our highest quarterly adjusted EBITDA in seven years. It was the first quarter with over $50 million in revenue since the second quarter of 2023. Our external customer chemistry revenue increased 50% sequentially. International revenues during the fourth quarter increased nearly 300% sequentially and exceeded the total from the first nine months of the year. And finally, roughly two-thirds of our data analytics revenue was derived from service contracts. As it relates to revenue, we inserted a new table into the press release to aid in quantifying components of revenue by segment. For our chemistry revenue, we segregated into related party versus external customers. And for the data analytics segment, we separated product versus service revenues. During the quarter, we grew total chemistry revenues 18% versus 4Q 2023. As compared to the year-ago quarter, we increased external customer chemistry revenue by 17% and related party chemistry revenue by 19%. As Ryan mentioned, the fourth quarter for external chemistry was very strong as we posted a 50% increase versus the third quarter of 2024. For data analytics, we grew revenue 74% versus the fourth quarter of 2023, which included a 124% increase in service revenue as compared to the year-ago quarter. Our fourth quarter 2024 service revenue of $1.6 million was the highest quarterly amount recorded since we acquired the business in 2020. Slide ten of the presentation shows our success in growing service revenue over the last four years. For 2024, service revenue made up 46% of total data analytics revenue versus only 35% in 2023. Fourth quarter gross profit increased 35% sequentially, representing a 600 basis point improvement as a percentage of revenue. Sequential margin improvement was driven by the significant jump in external customer chemistry revenues, the 67% sequential increase in data analytics service revenue, and an increase attributable to the order shortfall penalty under our long-term supply agreement. As shown on slide four, during 2024, gross profit margin totaled 21%, handily beating 2023 gross margin of 13%. On the SG&A front, 2024 SG&A costs declined 11%, approximately $3 million compared to last year, and SG&A was down 17% from 2023, when factoring in non-cash stock compensation costs. Costs associated with our annual grant made in October. But we do expect quarterly SG&A to trend back down in the first quarter. Net income for 2024 totaled $10.5 million or $0.34 per diluted share. During 2023, we reported a net loss of approximately $10 million or a net loss of $0.10 per share after backing out non-gains that were realized during 2023. For the quarter, our earnings per share totaled $0.14, that's a 75% increase from the third quarter of 2024. As shown on slide six in the presentation, during the fourth quarter, we continued our streak of up into the right with respect to adjusted EBITDA. The fourth quarter represented the ninth consecutive quarter improvement. Fourth quarter adjusted EBITDA was up 46% sequentially. As Ryan mentioned, as it relates to our guidance on annual adjusted EBITDA, the $20.3 million we posted for 2024 easily exceeded the top end of our guidance range of $18.5 million. Regarding 2025 guidance, consistent with our practice in 2024 and 2023, we expect to issue guidance in connection with our first quarter results. Touching on the balance sheet at year-end, we had $4.8 million drawn under our ABL. Currently, we have nothing drawn on our ABL. Our current year-end debt to adjusted EBITDA totaled 0.2x versus year-end 2023 of 5x. Significant improvement was driven by the over 12% increase in adjusted EBITDA versus 2023. In closing, we obviously set a very high bar with respect to our fourth quarter results. As we turn the focus to 2025, we look forward to continuing the operational and financial momentum we have established over the last several quarters. With that, I'll turn the call back to Ryan for closing comments.